Pluristem Therapeutics Inc (PSTI.OQ)
23 Jan 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|45||2017||Chairman of the Board, Chief Executive Officer|
|61||2017||President, Co-Chief Executive Officer, Director|
|49||2017||Chief Financial Officer|
|62||2006||Lead Independent Director|
- BRIEF-Pluristem Therapeutics Says Co Sold Its Entire Holdings In CHA Biotech Co For About $10.5 Mln
- BRIEF-FDA Clears Pluristem’s Expanded Access Program To Initiate Treatments Of Critical Limb Ischemia
- BRIEF-Pluristem enters agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD
- BRIEF-PLURISTEM PRICES PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE
- BRIEF-Pluristem extends trial for treatment of insufficient hematopoietic recovery